Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is a Chicago-based clinical-stage healthcare company specializing in AI-powered epigenetic cardiovascular diagnostic tests. The company completed its business combination in 2022 with Mana Capital Acquisition Corp, a blank-check company sponsored by Mana Capital LLC, and began trading on Nasdaq under the CDIO ticker following the close of that transaction. Operating in the healthcare diagnostics sector, Cardio Diagnostics develops DNA-methylation-based tests designed to assess cardiovascular disease risk, with a focus on early detection. The company filed an 8-K with the SEC on October 15, 2025, reflecting its continued status as a reporting public company. Visit SpacDesk and sign up for full data, filings history, and analytics on CDIO and hundreds of other SPAC-linked companies.